|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.56 EUR | +1.45% |
|
+7.29% | -0.12% |
| 07-12 | SCHOTT PHARMA : Deutsche Bank reiterates its Buy rating | ZD |
| 07-03 | SCHOTT PHARMA : Jefferies remains Neutral | ZD |
SCHOTT Pharma AG & Co. KGaA reported earnings results for the full year ended September 30, 2023. For the full year, the company reported sales was EUR 898.6 million compared to EUR 821.14 million a year ago.
Net income was EUR 151.84 million compared to EUR 125.38 million a year ago. Basic earnings per share from continuing operations was EUR 1.01 compared to EUR 0.83 a year ago. Diluted earnings per share from continuing operations was EUR 1.01 compared to EUR 0.83 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -0.12% | 5.44B | |
| -6.68% | 179B | |
| -5.20% | 98.84B | |
| -5.38% | 65.34B | |
| +15.46% | 45.41B | |
| -6.47% | 44.94B | |
| +9.74% | 43.76B | |
| +14.01% | 29.01B | |
| +19.39% | 25.65B | |
| -6.53% | 23.32B |
SCHOTT PHARMA AG & CO. KGAA 
